| 1 |
Eslam M, Sanyal AJ, George J. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease [J]. Gastroenterology, 2020, 158(7): 1999-2014. e1.
|
| 2 |
Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement [J]. J Hepatol, 2020, 73(1): 202-209.
|
| 3 |
Nan Y, An J, Bao J, et al. The Chinese society of hepatology position statement on the redefinition of fatty liver disease [J]. J Hepatol, 2021, 75(2): 454-461.
|
| 4 |
Wang X, Wu S, Yuan X, et al. Metabolic dysfunction-associated fatty liver disease and mortality among Chinese adults: a prospective cohort study [J]. J Clin Endocrinol Metab, 2022, 107(2): e745-e755.
|
| 5 |
Wang QX, Xue J, Shi MJ, et al. Association between metabolic dysfunction-associated fatty liver disease and the risk of cirrhosis in patients with chronic hepatitis B-A retrospective cohort study [J]. Diabetes Metab Syndr Obes, 2022, 15: 2311-2322.
|
| 6 |
Lim GEH, Tang A, Ng CH, et al. An observational data meta-analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD [J]. Clin Gastroenterol Hepatol, 2023, 21(3): 619-629. e7.
|
| 7 |
Ayada I, van Kleef LA, Alferink LJM, et al. Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: focusing on the non-overlap groups [J]. Liver Int, 2022, 42: 277-287.
|
| 8 |
Wong VW, Wong GL, Woo J, et al. Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease [J]. Clin Gastroenterol Hepatol, 2021, 19: 2161-2171.
|
| 9 |
Chen YL, Li H, Li S, et al. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study [J]. BMC Gastroenterol, 2021, 21: 212.
|
| 10 |
Huang YP, Zhang S, Zhang M, et al. Gender-specific prevalence of metabolic-associated fatty liver disease among government employees in Tianjin, China: a cross-sectional study [J]. BMJ Open, 2021, 11: e056260.
|
| 11 |
Guan C, Fu S, Zhen D, et al. Metabolic (dysfunction)-associated fatty liver disease in Chinese patients with type 2 diabetes from a subcenter of the national metabolic management center [J]. J Diabetes Res, 2022, 2022: 8429847.
|
| 12 |
Fouad Y, Esmat G, Elwakil R, et al. The egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease [J]. Saudi J Gastroenterol, 2022, 28(1): 3-20.
|
| 13 |
Shao CX, Ye J, Dong Z, et al. Steatosis grading consistency between controlled attenuation parameter and MRI-PDFF in monitoring metabolic associated fatty liver disease [J]. Ther Adv Chronic Dis, 2021, 12: 20406223211033119.
|
| 14 |
Ye J, Zhuang X, Li X, et al. Novel metabolic classification for extrahepatic complication of metabolic associated fatty liver disease: A data-driven cluster analysis with international validation [J]. Metabolism, 2022, 136: 155294.
|
| 15 |
Yu Q, Wu L, Ji J, et al. Gut Microbiota, peroxisome proliferator-activated receptors, and hepatocellular carcinoma [J]. J Hepatocell Carcinoma, 2020, 7: 271-288.
|
| 16 |
Seo DO, Holtzman DM. Gut microbiota: from the forgotten organ to a potential key player in the pathology of Alzheimer's disease [J]. J Gerontol A Biol Sci Med Sci, 2020, 75(7): 1232-1241.
|
| 17 |
Wu J, Wang K, Wang X, et al. The role of the gut microbiome and its metabolites in metabolic diseases [J]. Protein Cell, 2021, 12(5): 360-373.
|
| 18 |
Chen J, Vitetta L. Gut Microbiota metabolites in NAFLD pathogenesis and therapeutic implications [J]. Int J Mol Sci, 2020, 21(15): 5214.
|
| 19 |
Vallianou N, Christodoulatos GS, Karampela I, et al. Understanding the role of the gut microbiome and microbial metabolites in non-alcoholic fatty liver disease: current evidence and perspectives [J]. Biomolecules, 2021, 12(1): 56.
|
| 20 |
Yang L, Dai Y, He H, et al. Integrative analysis of gut microbiota and fecal metabolites in metabolic associated fatty liver disease patients [J]. Front Microbiol, 2022, 13: 969757.
|
| 21 |
Riordan SM, Duncombe VM, Thomas MC, et al. Small intestinal bacterial overgrowth, intestinal permeability, and non-alcoholic steatohepatitis [J]. Gut, 2002, 50(1): 136-138.
|
| 22 |
Zhu L, Baker SS, Gill C, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH [J]. Hepatology, 2013, 57(2): 601-609.
|
| 23 |
Raman M, Ahmed I, Gillevet PM, et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease [J]. Clin Gastroenterol Hepatol, 2013, 11(7): 868-875.e1-3.
|
| 24 |
Da Silva HE, Teterina A, Comelli EM, et al. Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance [J]. Sci Rep, 2018, 8(1): 1466.
|
| 25 |
Wang B, Jiang X, Cao M, et al. Altered Fecal microbiota correlates with liver biochemistry in nonobese patients with non-alcoholic fatty liver disease [J]. Sci Rep, 2016, 6: 32002.
|
| 26 |
Schwimmer JB, Johnson JS, Angeles JE, et al. Microbiome signatures associated with steatohepatitis and moderate to severe fibrosis in children with nonalcoholic fatty liver disease [J]. Gastroenterology, 2019, 157(4): 1109-1122.
|
| 27 |
Li F, Ye J, Shao C, Zhong B. Compositional alterations of gut microbiota in nonalcoholic fatty liver disease patients: a systematic review and Meta-analysis [J]. Lipids Health Dis, 2021, 20(1): 22.
|
| 28 |
Loomba R, Seguritan V, Li W, et al. Gut microbiome-based metagenomic signature for mon-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease [J]. Cell Metab, 2019, 30(3): 607.
|
| 29 |
Michail S, Lin M, Frey MR, et al. Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease [J]. FEMS Microbiol Ecol, 2015, 91(2): 1-9.
|
| 30 |
Li NN, Li W, Feng JX, et al. High alcohol-producing Klebsiella pneumoniae causes fatty liver disease through 2,3-butanediol fermentation pathway in vivo [J]. Gut Microbes, 2021, 13(1): 1979883.
|
| 31 |
Schroeder BO, Birchenough G, Ståhlman M, et al. Bifidobacteria or fiber protects against diet-induced microbiota-mediated colonic mucus deterioration [J]. Cell Host Microbe, 2018, 23(1): 27-40. e7.
|
| 32 |
Jia W, Rajani C. The influence of gut microbial metabolism on the development and progression of non-alcoholic fatty liver disease [J]. Adv Exp Med Biol, 2018, 1061: 95-110.
|
| 33 |
Luther J, Garber JJ, Khalili H, et al. Hepatic injury in nonalcoholic steatohepatitis contributes to altered intestinal permeability [J]. Cell Mol Gastroenterol Hepatol, 2015, 1(2): 222-232.
|
| 34 |
Zhang Z, Zhang H, Chen T, et al. Regulatory role of short-chain fatty acids in inflammatory bowel disease [J]. Cell Commun Signal, 2022, 20(1): 64.
|
| 35 |
Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy [J]. J Hepatol, 2020, 72(3): 558-577.
|
| 36 |
Markowiak-Kopeć P, Śliżewska K. The effect of probiotics on the production of short-chain fatty acids by human intestinal microbiome [J]. Nutrients, 2020, 12(4): 1107.
|
| 37 |
Nicholson JK, Holmes E, Kinross J, et al. Host-gut microbiota metabolic interactions [J]. Science, 2012, 336(6086): 1262-1267.
|
| 38 |
Liu W, Luo X, Tang J, et al. A bridge for short-chain fatty acids to affect inflammatory bowel disease, type 1 diabetes, and non-alcoholic fatty liver disease positively: by changing gut barrier [J]. Eur J Nutr, 2021, 60(5): 2317-2330.
|
| 39 |
Zhang S, Zhao J, Xie F, et al. Dietary fiber-derived short-chain fatty acids: A potential therapeutic target to alleviate obesity-related nonalcoholic fatty liver disease [J]. Obes Rev, 2021, 22(11): e13316.
|
| 40 |
Deng M, Qu F, Chen L, et al. SCFAs alleviated steatosis and inflammation in mice with NASH induced by MCD [J]. J Endocrinol, 2020, 245(3): 425-437.
|
| 41 |
Kolodziejczyk AA, Zheng D, Shibolet O, et al. The role of the microbiome in NAFLD and NASH [J]. EMBO Mol Med, 2019, 11(2): e9302.
|
| 42 |
Newton R, Priyadharshini B, Turka LA. Immunometabolism of regulatory T cells [J]. Nat Immunol, 2016, 17(6): 618-625.
|
| 43 |
Godlewska U, Bulanda E, Wypych TP. Bile acids in immunity: bidirectional mediators between the host and the microbiota [J]. Front Immunol, 2022, 13: 949033.
|
| 44 |
Li T, Chiang J. Bile acid-based therapies for non-alcoholic steatohepatitis and alcoholic liver disease [J]. Hepatobiliary Surg Nutr, 2020, 9(2): 152-169.
|
| 45 |
Li Y, Chen H, Ke Z, et al. Identification of isotschimgine as a novel farnesoid X receptor agonist with potency for the treatment of obesity in mice [J]. Biochem Biophys Res Commun, 2020, 521(3): 639-645.
|
| 46 |
Gillard J, Clerbaux LA, Nachit M, et al. Bile acids contribute to the development of non-alcoholic steatohepatitis in mice [J]. JHEP Rep, 2022, 4(1): 100387.
|
| 47 |
Rivera-Andrade A, Petrick JL, Alvarez CS, et al. Circulating bile acid concentrations and non-alcoholic fatty liver disease in Guatemala [J]. Aliment Pharmacol Ther, 2022, 56(2): 321-329.
|
| 48 |
Puri P, Daita K, Joyce A, et al. The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids [J]. Hepatology, 2018, 67: 534-548.
|
| 49 |
Ni Y, Lu M, Xu Y, et al. The role of gut microbiota-bile acids axis in the progression of non-alcoholic fatty liver disease [J]. Front Microbiol, 2022, 13: 908011.
|
| 50 |
Winston JA, Theriot CM. Diversification of host bile acids by members of the gut microbiota [J]. Gut Microbes, 2020, 11(2): 158-171.
|
| 51 |
Jadhav K, Xu Y, Xu Y, et al. Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR [J]. Mol Metab, 2018, 9: 131-140.
|
| 52 |
Siddiqui MS, Van Natta ML, Connelly MA, et al. Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis [J]. J Hepatol, 2020, 72(1): 25-33.
|
| 53 |
Arias N, Arboleya S, Allison J, et al. The relationship between choline bioavailability from diet, intestinal microbiota composition, and its modulation of human diseases [J]. Nutrients, 2020, 12: 2340.
|
| 54 |
Ji Y, Yin Y, Sun L, et al. The molecular and mechanistic insights based on gut-liver axis: nutritional target for non-alcoholic fatty liver disease (NAFLD) improvement [J]. Int J Mol Sci, 2020, 21(9): 3066.
|
| 55 |
Tan X, Liu Y, Long J, et al. Trimethylamine N-oxide aggravates liver steatosis through modulation of bile acid metabolism and inhibition of farnesoid X receptor signaling in nonalcoholic fatty liver disease [J]. Mol Nutr Food Res, 2019, 63(17): e1900257.
|
| 56 |
Yang S, Li X, Yang F, et al. Gut microbiota-dependent marker TMAO in promoting cardiovascular disease: inflammation mechanism, clinical prognostic, and potential as a therapeutic target [J]. Front Pharmacol, 2019, 10: 1360.
|
| 57 |
Hernandez GV, Smith VA, Melnyk M, et al. Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH [J]. Am J Physiol Gastrointest Liver Physiol, 2020, 318: G582-G609.
|
| 58 |
Carpino G, Del Ben M, Pastori D, et al. Increased liver Localization of lipopolysaccharides in human and experimental NAFLD [J]. Hepatology, 2020, 72: 470-485.
|
| 59 |
Takeuchi O, Akira S. Pattern recognition receptors and inflammation [J]. Cell, 2010, 140(6): 805-820.
|
| 60 |
Chassaing B, Ley RE, Gewirtz AT. Intestinal epithelial cell toll-like receptor 5 regulates the intestinal microbiota to prevent low-grade inflammation and metabolic syndrome in mice [J]. Gastroenterology, 2014, 147(6): 1363-77. e17.
|
| 61 |
Zhu L, Baker RD, Zhu R, et al. Gut microbiota produce alcohol and contribute to NAFLD [J]. Gut, 2016, 65(7): 1232.
|
| 62 |
Yuan J, Chen C, Cui J, et al. Fatty liver disease caused by high-alcohol-producing Klebsiella pneumoniae [J]. Cell Metab, 2019, 30(4): 675-688.e7.
|
| 63 |
Wu L, Mo W, Feng J, et al. Astaxanthin attenuates hepatic damage and mitochondrial dysfunction in non-alcoholic fatty liver disease by up-regulating the FGF21/PGC-1α pathway [J]. Br J Pharmacol, 2020, 177(16): 3760-3777.
|
| 64 |
Trovato FM, Catalano D, Martines GF, et al. Mediterranean diet and non-alcoholic fatty liver disease: the need of extended and comprehensive interventions [J]. Clin Nutr, 2015, 34(1): 86-88.
|
| 65 |
Da Silva HE, Arendt BM, Noureldin SA, et al. A cross-sectional study assessing dietary intake and physical activity in Canadian patients with nonalcoholic fatty liver disease vs healthy controls [J]. J Acad Nutr Diet, 2014, 114(8): 1181-1194.
|
| 66 |
Nielsen LS, Danielsen KV, Sørensen TI. Short sleep duration as a possible cause of obesity: critical analysis of the epidemiological evidence [J]. Obes Rev, 2011, 12(2): 78-92.
|
| 67 |
Brondel L, Romer MA, Nougues PM, et al. Acute partial sleep deprivation increases food intake in healthy men [J]. Am J Clin Nutr, 2010, 91(6): 1550-1559.
|
| 68 |
St George A, Bauman A, Johnston A, et al. Independent effects of physical activity in patients with nonalcoholic fatty liver disease [J]. Hepatology, 2009, 50(1): 68-76.
|
| 69 |
Munukka E, Ahtiainen JP, Puigbó P, et al. Six-week endurance exercise alters gut metagenome that is not reflected in systemic metabolism in over-weight women [J]. Front Microbiol, 2018, 9: 2323.
|
| 70 |
Sheka AC, Adeyi O, Thompson J, et al. Nonalcoholic steatohepatitis: A review [J]. Jama, 2020, 323(12): 1175-1183.
|
| 71 |
Jiang C, Xie C, Li F, et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease [J]. J Clin Invest, 2015, 125(1): 386-402.
|
| 72 |
Abdel-Razik A, Mousa N, Shabana W, et al. Rifaximin in nonal-coholic fatty liver disease: hit multiple targets with a single shot [J]. Eur J Gastroenterol Hepatol, 2018, 30(10): 1237-1246.
|
| 73 |
Jian J, Nie MT, Xiang B, et al. Rifaximin ameliorates non-alcoholic steatohepatitis in mice through regulating gut microbiome-related bile acids [J]. Front Pharmacol, 2022, 13: 841132.
|
| 74 |
Ebrahimzadeh Leylabadlo H, Ghotaslou R, Samadi Kafil H, et al. Non-alcoholic fatty Liver diseases: from role of gut microbiota to microbial-based therapies [J]. Eur J Clin Microbiol Infect Dis, 2020, 39(4): 613-627.
|
| 75 |
Mohammed SK, Magdy YM, El-Waseef DA, et al. Modulation of hippocampal TLR4/BDNF signal pathway using probiotics is a step closer towards treating cognitive impairment in NASH Model [J]. Physiol Behav, 2020, 214: 112762.
|
| 76 |
Tang Y, Huang J, Zhang WY, et al. Effects of probiotics on nonalco-holic fatty liver disease: a systematic review and meta-analysis [J]. Therap Adv Gastroenterol, 2019, 12: 1756284819878046
|
| 77 |
Bomhof MR, Parnell JA, Ramay HR, et al. Histological improvement of non-alcoholic steatohepatitis with a prebiotic: A pilot clinical trial [J]. Eur J Nutr (2019) 58: 1735-1745.
|
| 78 |
van der Beek CM, Canfora EE, Kip AM, et al. The prebiotic inulin improves substrate metabolism and promotes short-chain fatty acid production in overweight to obese men [J]. Metabolism, 2018, 87, 25-35.
|
| 79 |
Kanchanasurakit S, Kositamongkol C, Lanoi K, et al. Effects of synbiotics, probiotics, and prebiotics on liver enzymes of patients with non-alcoholic fatty liver disease: A systematic review and network meta-analysis [J]. Front Nutr, 2022, 9: 880014.
|
| 80 |
Liu L, Li P, Liu Y, Zhang Y. Efficacy of probiotics and synbiotics in patients with nonalcoholic fatty liver disease: a meta-analysis [J]. Dig Dis Sci, 2019, 64(12): 3402-3412.
|
| 81 |
Kelly CR, Yen EF, Grinspan AM, et al. Fecal microbiota transplantation is highly effective in real-world practice: initial results from the FMT national registry [J]. Gastroenterology, 2021, 160: 183-192. e3.
|
| 82 |
de Groot P, Nikolic T, Pellegrini S, et al. Faecal Microbiota transplantation halts progression of human new-onset type 1 diabetes in a randomised controlled trial [J]. Gut, 2021, 70: 92-105.
|
| 83 |
Holvoet T, Joossens M, Vázquez-Castellanos JF, et al. Fecal microbiota transplantation reduces symptoms in some patients with irritable bowel syndrome with predominant abdominal bloating: short- and long-term results from a placebo-controlled randomized trial [J]. Gastroenterology, 2021, 160: 145-157. e8.
|
| 84 |
Witjes JJ, Smits LP, Pekmez CT, et al. Donor fecal microbiota transplantation alters gut microbiota and metabolites in obese individuals with steatohepatitis [J]. Hepatol Commun, 2020, 4: 1578-1590.
|
| 85 |
Craven L, Rahman A, Nair Parvathy S, et al. Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: A randomized control trial [J]. Am J Gastroenterol, 2020, 115: 1055-1065.
|